Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma: Observational, Multicenter, Real-world Study
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients over 18 years of age
• Metastatic urothelial carcinoma
• Treated with first-line metastatic therapy since October 2024
Locations
Other Locations
France
Service Oncologie Médicale - CHU de Strasbourg - France
RECRUITING
Strasbourg
Contact Information
Primary
Philippe Barthélémy, MD
philippe.barthelemy@chru-strasbourg.fr
33 3 88 12 76 70
Time Frame
Start Date: 2025-04-20
Estimated Completion Date: 2026-04-20
Participants
Target number of participants: 50
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Strasbourg, France